Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating and/or preventing cancer and application

A drug and cancer technology, applied in drug combinations, medical preparations containing active ingredients, anti-tumor drugs, etc., can solve problems such as failure, prolong patient survival, and fail to improve the clinical efficacy of PD-1 monotherapy

Pending Publication Date: 2020-06-19
长春康悦生物科技有限公司
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Both prolong the survival of patients by 4 months and 4.4 months in phase III clinical trials, and both can only produce moderate clinical benefits
Then there are also failure cases of cancer vaccines combined with PD-1 antibodies, in which PD-1 antibody combined with peptide vaccines failed to improve the clinical efficacy of PD-1 monotherapy in phase I clinical trials of refractory and untreated melanoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating and/or preventing cancer and application
  • Medicine for treating and/or preventing cancer and application
  • Medicine for treating and/or preventing cancer and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] 1. Materials

[0037] Experimental reagents: The recombinant MUC1-MBP fusion protein vaccine was prepared according to the sequence shown in SEQ ID NO.1 by conventional vaccine preparation methods. Anti-PD-1 antibody RMP1-14 and rat IgG 2a isotype control antibody were purchased from BioXcell. Sterile water for injection and normal saline were purchased from Sichuan Kelun Pharmaceutical Co., Ltd.

[0038] Experimental animals: C57 BL / 6 mice (SPF grade, half male and half male, 6-8 weeks old, body weight 18-22 g) were purchased from Shenyang Changsheng Biotechnology Co., Ltd.

[0039] 2. Method

[0040] 2.1 Immunization of mice

[0041] The mice were weighed and randomly divided into groups of 10 mice each, including normal saline control group (NS group), immune checkpoint inhibitor anti-PD-1 antibody injection group (PD-1 group), and recombinant MUC-MBP fusion group. Protein vaccine group (vaccine group), recombinant MUC-MBP fusion protein vaccine preparation combin...

Embodiment 2

[0052] 1. Materials

[0053] Experimental reagents: The recombinant MUC1-MBP fusion protein vaccine was prepared according to the sequence shown in SEQ ID NO.1 by conventional vaccine preparation methods. Anti-PD-1 antibody RMP1-14 and ratIgG2a isotype control antibody were purchased from BioXcell. Sterile water for injection and normal saline were purchased from Sichuan Kelun Pharmaceutical Co., Ltd. Experimental animals: C57BL / 6 mice (SPF grade, half male and half male, 6-8 weeks old, weighing 18-22 g) were purchased from Shenyang Changsheng Biotechnology Co., Ltd.

[0054] 2. Method

[0055] 2.1 Effect of recombinant MUC1-MBP fusion protein vaccine combined with anti-PD-1 antibody on mouse CTL killing activity

[0056] CTL killing is the gold standard for evaluating antitumor effects. In order to verify whether recombinant MUC1-MBP fusion protein vaccine combined with PD-1 antibody treatment can induce stable MUC1-specific CTL killing in mice. As mentioned above, on the...

Embodiment 3

[0062] 1. Materials

[0063] Experimental reagents: The recombinant MUC1-MBP fusion protein vaccine was prepared according to the sequence shown in SEQ ID NO.1 by conventional vaccine preparation methods. Anti-PD-1 antibody RMP1-14 and rat IgG2a isotype control antibody were purchased from BioXcell. Sterile water for injection and normal saline were purchased from Sichuan Kelun Pharmaceutical Co., Ltd. MUC1 polypeptide was synthesized by Shanghai Ziyu Biotechnology Co., Ltd., goat anti-mouse IgG2c-HRP and rat anti-mouse IgG1-HRP were purchased from SouthernBiotech, and goat anti-mouse IgG (H+L) was purchased from Proteintech. Experimental animals: C57 BL / 6 mice (SPF grade, half male and half male, 6-8 weeks old, body weight 18-22 g) were purchased from Shenyang Changsheng Biotechnology Co., Ltd.

[0064] 2. Method

[0065] 2.1 Effect of recombinant MUC1-MBP fusion protein vaccine combined with anti-PD-1 antibody on the production of MUC1-specific antibodies and subclasses

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating and / or preventing cancer and an application. The medicine of the invention includes a recombinant MUC1-MBP fusion protein vaccine and a PD-1 antibody.The medicine is expected to break an immune tolerance state of a tumor microenvironment in vivo and enhance the MUC1 specific anti-tumor immune response, and is expected to completely clear tumors tobring gospel to the majority of cancer patients.

Description

technical field [0001] The invention relates to the technical field of immunological therapeutic drugs, in particular to a drug for treating and / or preventing cancer and its application. Background technique [0002] Cancer vaccine is an active immunotherapy that specifically kills cancer cells by targeting tumor antigens. Cancer vaccines mainly include DNA vaccines, DC vaccines, oncolytic virus vaccines or recombinant virus vector vaccines, and peptide or protein-based vaccines. So far, most cancer vaccine research is in phase I-II clinical trials, more than 10 products have entered phase III clinical trials, and there are two therapeutic cancer vaccines on the market: one is the prostate cancer vaccine approved by the US FDA in 2010 Cancer Provenge vaccine, and the second is the T-VEC vaccine approved by the US FDA in 2015 for the treatment of advanced melanoma. In phase III clinical trials, the two prolong the survival period of patients by 4 months and 4.4 months respec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K39/00A61P35/00A61P37/04
CPCA61K39/3955A61K39/001102A61P35/00A61P37/04A61K2039/575A61K2039/57A61K2039/505A61K2300/00
Inventor 台桂香
Owner 长春康悦生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com